# Diagnostic accuracy of pre-operative NT-proBNP level in predicting short-term outcomes in coronary surgery: a pilot study

Łukasz J. Krzych<sup>1, 2</sup>, Dariusz Szurlej<sup>1</sup>, Tadeusz Kołodziej<sup>1</sup>, Leszek Machej<sup>1</sup>, Andrzej Węglarzy<sup>1</sup>, Andrzej Błach<sup>3</sup>, Mirosław Wilczyński<sup>2</sup>, Stanisław Woś<sup>3</sup>, Andrzej Bochenek<sup>2</sup>

#### Abstract

**Background:** B-type natriuretic peptides (BNP) are acknowledged markers of acute and chronic heart failure. Insufficient data exist, however, regarding their diagnostic usefulness in cardiac surgery, particularly in coronary patients.

**Aim:** To assess diagnostic accuracy of preoperative value of NT-proBNP level as a predictor of short-term postoperative complications in subjects undergoing coronary artery bypass grafting (CABG).

**Methods:** This pilot study included 100 consecutive patients scheduled for elective CABG, including 24 females and 76 males (mean age  $65.9 \pm 9.1$  years). Exclusion criteria were: significant valvular disorders, off-pump procedure, renal failure (GFR <  $60 \text{ mL/min/}1.73 \text{ m}^2$ ), low ejection fraction (< 30%), intra-aortic balloon pump counterpulsation (IABP), use of inotropic agents, atrial fibrillation (AF), and implanted pacemaker or defibrillator. The NT-proBNP level was measured on the day of the surgery before induction of anaesthesia. We investigated short-term postoperative complications, defined as those occurring within 30 days or before hospital discharge.

Results: Median NT-proBNP concentration was 526.0 pg/mL (IQR 156.0–1150.0). None of patients died postoperatively. Excessive drainage (> 850 mL) was found in 13 (13%) patients and 22 (22%) subjects required transfusions. Prolonged mechanical ventilation (> 12 h) was necessary in 15 (15%) patients and respiratory failure occurred in 2 (2%) of them. Postoperative AF was present in 34 (34%) subjects. Perioperative myocardial infarction was diagnosed in 2 (2%) persons. Low cardiac output was present in 9 (9%) patients. Haemodynamic support with the use of IABP was necessary in 7 (7%) patients and inotropic drugs were used in 61 (61%) subjects. Stroke or delirium was diagnosed in 1 (1%) subject. The NT-proBNP level correlated with the operative risk estimated by logistic and additive EuroSCORE: r = 0.558 (95% CI 0.406–0.680; p < 0.001) and r = 0.551 (95% CI 0.397–0.674; p < 0.001), respectively. The NT-proBNP level correlated significantly with the length of Intensive Care Unit (ICU) stay and hospital stay: r = 0.412 (95% CI 0.238–0.566; p < 0.001) and r = 0.547 (95% CI 0.393–0.672; p < 0.001), respectively. The NT-proBNP level was a predictor of postoperative prolonged mechanical ventilation, respiratory failure, AF, IABP use, inotropic support and postoperative platelet transfusions (p < 0.05 for all). However, good or very good diagnostic accuracy was found only in relation to mechanical ventilation (AUROC = 0.854), respiratory insufficiency (AUROC = 0.867), IABP use (AUROC = 0.889), and milirinone use (AUROC = 0.929).

**Conclusions:** Preoperative assessment of NT-proBNP level in CABG patients could be a valuable diagnostic method for predicting several postoperative complications, especially pulmonary outcomes and requirement for haemodynamic support, and it correlated with the length of ICU stay and hospital stay.

Key words: coronary artery bypass grafting, NT-proBNP, diagnostic accuracy, postoperative complications

Kardiol Pol 2011; 69, 11: 1121-1127

#### Address for correspondence:

Eukasz Krzych, MD, PhD, 1st Department of Cardiac Surgery, Medical University of Silesia, SPSK nr 7, ul. Ziołowa 45/47, 40–635 Katowice, Poland, tel: +48 32 359 86 11, fax: +48 32 252 60 44, e-mail: l.krzych@wp.pl

**Received:** 10.03.2011 **Accepted:** 18.05.2011 Copyright © Polskie Towarzystwo Kardiologiczne

<sup>&</sup>lt;sup>1</sup>Department of Cardiac Anaesthesia and Postoperative Intensive Care, Medical University of Silesia, Katowice-Ochojec, Poland

<sup>&</sup>lt;sup>2</sup>1st Department of Cardiac Surgery, Medical University of Silesia, Katowice-Ochojec, Poland

<sup>&</sup>lt;sup>3</sup>2<sup>nd</sup> Department of Cardiac Surgery, Medical University of Silesia, Katowice-Ochojec, Poland

1122 Łukasz J. Krzych et al.

### INTRODUCTION

B-type natriuretic peptides (BNP) and N-terminal BNP propeptide (NT-proBNP) are established markers of acute and chronic heart failure (HF) [1, 2]. Their level reflects the haemodynamic status and has a prognostic value, as it correlates with mortality and morbidity even in patients without overt HF [2–4]. The use of natriuretic peptides as a population screening tool to detect left ventricular (LV) dysfunction is, however, limited [5].

Monitoring BNP and NT-proBNP levels has been successfully used to evaluate cardiovascular (CV) status in patients acutely admitted to emergency departments [6], patients with cardiac arrhythmia and patients undergoing heart transplantation [7]. Still little is known, however, on their utility in patients undergoing cardiac surgery, including surgery for coronary artery disease. Monitoring BNP and NT-proBNP levels might help evaluate operative risk and predict postoperative complications.

Our study aimed to assess diagnostic accuracy of preoperative value of NT-proBNP level as a predictor of shortterm postoperative complications in subjects undergoing coronary artery bypass grafting (CABG).

# METHODS Study group

Upon approval of the Ethics Committee and obtaining written patient consent, the study group was recruited from consecutive 900 patients referred for elective CABG between September 2009 and June 2010. Exclusion criteria included significant valve disease (requiring surgical correction), off--pump procedure, preoperative chronic kidney disease (glomerular filtration rate — GFR < 60 mL/min/1.73 m<sup>2</sup>), severely decreased LV ejection fraction (LVEF < 30%), preoperative intra-aortic balloon pump counterpulsation (IABP) or use of inotropic agents, preoperative atrial fibrillation (AF), and implanted pacemaker or defibrillator. Overall, 100 patients fulfilling the above criteria were included into the study. We determined their exact clinical profile including demographic variables, concomitant disease, HF symptoms categorised using the New York Heart Association (NYHA) functional classification, and the operative risk determined by logistic and additive EuroSCORE.

# The NT-proBNP level determination

The NT-proBNP level was measured on the day of the surgery before induction of anaesthesia. The ECLIA (Electrochemiluminescence, Elecsys 2010, Roche Diagnostics) was used to assess NT-proBNP concentration in venous blood.

# Post-operative complications

We investigated postoperative complications including early deaths (within 30 days or before hospital discharge), excessive drainage (defined as exceeding the 90. percentile of the observed values), need for blood transfusion, respiratory fa-

ilure, need for prolonged mechanical ventilation (> 12 h), AF, myocardial infarction (MI), low cardiac output syndrome, need for haemodynamic support using IABP or inotropic drugs, central nervous system ischaemia or delirium, acute renal failure, and splanchnic ischaemia. Acute respiratory distress syndrome was diagnosed in subjects requiring prolonged mechanical ventilation to combat or prevent hypoxaemia due to an inflammatory process, impaired perfusion or other forms of capillary transport disturbances.

# Statistical analysis

Statistical analysis was performed using procedures of the MedCalc software. Quantitative variables are presented as mean values and standard deviations (normally distributed variables) or median values and interquartile ranges (IQR) (non-normally distributed variables), and qualitative variables as absolute numbers and percentages. Correlations between quantitative variables were evaluated using the Pearson linear correlation coefficient, if necessary after logarithmic transformation. Diagnostic accuracy was analysed on the basis of the area under the ROC curve (AUROC). A p value < 0.05 was considered statistically significant.

#### **RESULTS**

The study included 24 women and 76 men. The mean patient age was  $65.9 \pm 9.1$  years. A detailed patient characteristics including comorbidities is shown in Table 1. The median baseline operative risk was 4 points (IQR 2–7) by additive EuroSCORE and 2.90% (IQR 1.75–8.40) by logistic EuroSCORE. Median NT-proBNP level was 526.0 pg/mL (IQR 156.0–1150.0).

The median time of cardiopulmonary bypass was 71 min (IQR 60–81), and the median time of aortic clamping was 48 min (IQR 46–54). Median of three bypass graft per patient were performed (IQR 3–3). The left anterior descending artery was grafted in 98 patients (including 96 arterial grafts), the left circumflex artery was grafted in 92 patients (all venous grafts), and the right coronary artery was grafted in 80 patients (all venous grafts); in addition, 13 grafts were performed to other coronary vessels (all venous grafts), resulting in complete revascularisation in all patients.

No postoperative deaths were noted. The median duration of stay in the postoperative Intensive Care Unit (ICU) was 2 days (IQR 2–2), and of total hospitalisation time was 7 days (IQR 6–8). Median postoperative drainage volume was 500 mL (IQR 400–735), and excessive drainage (> 850 mL) was noted in 13 (13%) patients. Blood product transfusions were necessary in 22 (22%) patients, including packed red cells in 22 (22%) patients, fresh frozen plasma in 16 (16%) patients, and platelets in 9 (9%) patients. Prolonged mechanical ventilation (> 12 h) was necessary in 15 (15%) patients, and respiratory failure was diagnosed in 2 (2%) patients, and perioperative AF was noted in 34 (34%) patients, and perioperative MI was diagnosed in 2 (2%) patients. Low cardiac out-

**Table 1.** Clinical characteristics of the studied patients

Women	24 (24%)		
Age [years]	65.9 ± 9.1		
Body weight [kg]	$75.2 \pm 13.3$		
Height [cm]	$169.6 \pm 7.7$		
Body mass index [kg/m²]	24.97 (23.42–26.84)		
Extent of coronary artery disease:			
LMD	37 (37%)		
LMD equivalent	7 (7%)		
LAD	100 (100%)		
Cx	90 (90%)		
RCA	85 (85%)		
NYHA class:			
I	2 (2%)		
II	81 (81%)		
III	17 (17%)		
IV	0 (0%)		
CCS class:			
0	3 (3%)		
1	4 (4%)		
2	44 (44%)		
3	44 (44%)		
4	5 (5%)		
Ejection fraction [%]	52.5 (45–60)		
LVESD [mm]	34 (31–40)		
LVEDD [mm]	52 (48–56)		
GFR [mL/min/1.73 m <sup>2</sup> ]	90 (75.5–90)		
Hypertension	67 (67%)		
Diabetes	33 (33%)		
Chronic obstructive pulmonary disease	28 (28%)		
Current smoking	19 (19%)		
Previous NSTEMI	24 (24%)		
Previous STEMI	9 (9%)		
Peripheral vascular disease	12 (12%)		
Previous stroke or TIA	9 (9%)		
Carotid artery disease	4 (4%)		
1			

Quantitative variables were presented as mean values and standard deviations (normally distributed variables) or median values and interquartile ranges (non-normally distributed variables), and qualitative variables as absolute numbers and percentages; CCS — Canadian Cardiovascular Society; Cx — circumflex artery; GFR — glomerular filtration rate; LAD — left anterior descending artery; LMD — left main disease; LVEDD — left ventricular end-diastolic dimension; LVESD — left ventricular end-systolic dimension; NYHA — New York Heart Association; RCA — right coronary artery, TIA — transient ischaemic attack; NSTEMI — non-ST elevation myocardial infarction; STEMI — ST elevation myocardial infarction

put syndrome was diagnosed in 9 (9%) patients. Haemodynamic support with IABP was necessary in 7 (7%) patients, and with inotropic drugs in 61 (61%) patients, most commonly with dopamine (60 patients), and more rarely with

adrenaline (10 patients) and milrinone (2 patients). Stroke occurred in 1 (1%) patients, as was delirum.

Preoperative NT-proBNP level showed a significant correlation with baseline risk by logistic EuroSCORE (r = 0.558; 95% CI 0.406–0.680; p < 0.001) and additive EuroSCORE (r = 0.551; 95% CI 0.397 – 0.674; p < 0.001). The NT-proBNP level showed a negative correlation with baseline GFR (r = -0.211; 95% CI -0.391 to -0.015; p = 0.04) but was not related to cardiopulmonary bypass duration (r = 0.111; 95% CI -0.094 to 3.07; p = 0.3) and a ortic clamping duration (r = -0.113; 95% CI -0.309 to 0.093; p = 0.3). Of note, LVEF showed a significant negative correlation with NT-proBNP level (r = -0.540; 95% CI -0.666 to -0.384; p < 0.01). The NT-proBNP levels were highest in patients with lowest LVEF (30-40%; median 1780.0 pg/mL; IQR 977.5-2861), lower in patients with LVEF of 41-50% (median 480 pg/mL; IQR 203.74-699.0), and lowest in patients with LVEF > 50% (median 306 pg/mL; IQR 99.8–999.0; p < 0.001). Relation between the number of grafts and NT--proBNP level approached statistical significance (r = 0.203; 95% CI 0.006-0.384; p = 0.05). The NT-proBNP levels were highest in patients with 4 grafts (median 908.5 pg/mL; IQR 260.5-999.0), lower in patients with 3 grafts (median 559.0 pg/mL; IQR 151.5-1335.0), and lowest in patients with 2 grafts (median 290.0 pg/mL; IQR 92.8-554.75). A weak, albeit statistically significant correlation was found between baseline NT-proBNP level and postoperative drainage volume (r = 0.244; 95% CI 0.050–0.421; p = 0.01).

Preoperative NT-proBNP level was a significant predictor of the need for prolonged ventilation, respiratory failure, AF, need for IABP, need for inotropic drugs (dopamine, adrenaline, and milrinone), and platelet transfusion. Good or very good diagnostic accuracy (AUROC > 0.8) in predicting postoperative complications was found only for the need for prolonged ventilation (AUROC = 0.854), respiratory failure (AUROC = 0.867), need for IABP (AUROC = 0.889), and need for milrinone (AUROC = 0.929). For the remaining complications, the diagnostic accuracy was moderate (AUROC 0.7 to 0.8) or weak (AUROC 0.6 to 0.7). These findings are summarised in Table 2 and Figures 1-4.

Preoperative NT-proBNP level showed a significant positive correlation with the length of ICU stay (r=0.412;95% CI 0.238–0.566; p<0.001) and total hospitalisation length (r=0.547;95% CI 0.393–0.672; p<0.001).


# **DISCUSSION**

The purpose of our study was to assess the usefulness of preoperative NT-proBNP measurements in predicting most common postoperative complications in patients undergoing CABG. We found that NT-proBNP measurements are particularly useful in predicting pulmonary outcomes and requirement for haemodynamic support with IABP. We also found that NT-proBNP level correlated with the length of ICU stay and total hospitalisation length. Of note, NT-proBNP 1124 Łukasz J. Krzych et al.


Table 2. Diagnostic accuracy of preoperative NT-proBNP level in predicting postoperative complications

Type of complication	AUROC (95% CI)	Cut-off	Р		
		Value [pg/mL]	Sensitivity [%]	Specificity [%]	
Prolonged mechanical ventilation (> 12 h)	0.854 (0.769–0.917)	> 1032	86.7	81.0	< 0.001
Respiratory failure	0.867 (0.785-0.927)	> 1443	100.0	86.7	0.03
Excessive drainage (> 850 mL)	0.625 (0.523-0.720)	> 1335	53.8	88.5	0.15
Any blood product transfusion	0.538 (0.436-0.639)	> 1335	31.8	87.2	0.59
Packed red cells transfusion	0.538 (0.436-0.639)	> 1335	31.8	87.2	0.57
Fresh frozen plasma transfusion	0.496 (0.395-0.598)	≤ 71	31.2	90.5	0.96
Platelet transfusion	0.683 (0.582-0.772)	≤ 71	55.6	91.2	0.03
Atrial fibrillaton	0.650 (0.548-0.743)	> 513	73.5	57.6	0.01
Myocardial infarction	0.571 (0.469–0.670)	> 324	100.0	42.9	0.74
Low cardiac output syndrome	0.642 (0.540-0.736)	> 1150	66.7	80.2	0.17
IABP	0.889 (0.811-0.943)	> 1032	100.0	76.3	< 0.001
Any inotropic drug	0.730 (0.632-0.814)	> 684	55.7	82.1	< 0.001
Dopamine	0.748 (0.651-0.829)	> 559	61.7	77.5	< 0.001
Adrenaline	0.697 (0.597–0.785)	> 1032	70.0	75.6	0.04
Milrinone	0.929 (0.859–0.970)	> 1340	100.0	85.7	< 0.001

AUROC — area under ROC curve; CI — confidence interval; IABP — intra-aortic balloon pump counterpulsation



**Figure 1**. The ROC curve for the diagnostic accuracy of NT-proBNP level in predicting the need for prolonged mechanical ventilation (> 12 h postoperatively)




**Figure 2.** The ROC curve for the diagnostic accuracy of NT-proBNP level in predicting postoperative respiratory failure


level was related to the extent of the surgery, with higher levels in patients with more grafts. The NT-proBNP level also correlated with the drainage volume.

These findings are mostly consistent with the current state of knowledge, although so far only few authors evaluated diagnostic accuracy of NT-proBNP measurements and reported potential cut-off values for predicting specific complications. In a study by Schachner et al. [8], preoperative level of

> 502 ng/mL was significantly related to prolonged ventilation time, length of ICU stay, the need for IABP and haemofiltration, and the incidence of AF (p = 0.03) in patients undergoing CABG. In another study in a similar group of patients, NT-proBNP level was a predictor of an ICU stay lasting longer than one day (OR 1.03 for each increase in NT-proBNP level by 250 ng/L) and total hospitalisation length above one week (OR 1.07 for each increase in NT-proBNP level by



**Figure 3.** The ROC curve for the diagnostic accuracy of NT-proBNP level in predicting the need for postoperative intra-aortic balloon pump counterpulsation use



**Figure 4.** The ROC curve for the diagnostic accuracy of NT-proBNP level in predicting the need for postoperative milrinone use

250 ng/L) [9]. Important findings were reported in a meta-analysis of studies evaluating the utility of preoperative NT-proBNP measurements in predicting early complications in patients undergoing vascular surgery [10]. In this study, BNP or NT-proBNP level was a significant predictor of the 30-day risk of a cardiac death (OR 7.6; 95% CI 1.33–43.4), non-fatal MI (OR 6.24; 95% CI 1.82–21.4), and a combined endpoint of major adverse cerebral and CV events (MACCE) (OR 17.37; 95% CI 3.31–91.15).

In turn, BNP level > 190 pg/mL was a predictor of an ICU stay lasting > 5 days (AUROC 0.712), and a level of

> 20.5 pg/mL predicted the need for dobutamine use (AUROC 0.842). The BNP level significantly correlated with the duration of ventilation support, the length of ICU stay, and the duration of dobutamine administration [11]. In another study [12] patients with highest preoperative BNP levels required significantly longer ventilation, more frequently required inotropic support, and were at a higher risk of one-year mortality. Similar findings were reported in other studies [13], including patients undergoing off-pump CABG [14]. In the study by Hutfless et al. [15], diagnostic accuracy of preoperative BNP level of > 385 pg/mL in predicting postoperative IABP use, the length of hospital stay  $\geq$  10 days, and one-year mortality was 86%, 79%, and 85%, respectively. These observations may also explain another quite interesting finding of our study, i.e. a relation between NT-proBNP level and postoperative drainage. Perhaps the latter is affected by baseline comorbidities and low EF, as indicated by a correlation between NT-proBNP level and the EuroSCORE risk. These results, however, require confirmation in larger patient populations.

The ability to predict postoperative AF based on preoperative BNP or NT-proBNP levels has not been clearly confirmed yet, although more studies support it [16–19] than refute it [13]. In regard to the diagnostic accuracy of natriuretic peptides in predicting pulmonary complications, a study by Kolditz et al. [20] should be mentioned, as it has documented a high diagnostic accuracy (> 90%) of NT-proBNP level of > 4000 ng/L in predicting pleural effusion due to cardiac causes. Similar findings have been reported for a cut-off BNP level of 2201 ng/L [21], and other data indicate an ability to predict obstructive sleep apnea [22].

It has also been shown that perioperative variability of NT-proBNP is a strong and independent predictor of complications (HR 3.06; 95% CI 1.36–6.91) in patients undergoing vascular surgery [23]. Similar data regarding the ability to predict LV function following cardiac surgery have been reported by Chello et al. [24]. It has also been documented that preoperative levels correlated better than postoperative values with the duration of hospitalisation and long-term mortality risk in patients undergoing coronary surgery [25].

# Limitations of the study

Our work had some potential limitations, mostly due to a limited number of patients in this pilot study. Only when our observations are confirmed in a larger group of patients, it will allow more precise estimation of cut-off values for predicting particular postoperative complications. In addition, some complications occur relatively rarely and thus we were unable to analyse the predictive value in regard to the risk of mortality, renal, neurological, and psychiatric complications, or a combined endpoint of MACCE. Duration of follow-up was also a limitation, as in-hospital data do not allow for evaluation of a long-term predictive ability. Finally, a more precise analysis should take into account other factors that influ-

1126 Łukasz J. Krzych et al.

ence natriuretic peptide levels, such as age, gender and severity of atherosclerosis, and thus are potential confounding factors [26–29], and also the issue of appropriate reporting of diagnostic accuracy in the published studies [30].

#### **CONCLUSIONS**

- Preoperative assessment of NT-proBNP level in CABG patients could be a valuable diagnostic method for predicting several postoperative complications, especially prolonged mechanical ventilation, respiratory failure, requirement for haemodynamic support using IABP or inotropic drugs, as well as the length of hospital stay.
- 2. Precise estimation of cut-off points for predicting the above-mentioned complications requires further research.

The study was supported by Śląski Uniwersytet Medyczny (grant No. KNW-1-206/08).

#### Conflict of interest: none declared

#### References

- Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison
  of the diagnostic accuracy of brain natriuretic peptide (BNP)
  and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin
  Chem, 2007; 53: 813–822.
- Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ, 2005; 330: 625.
- Wita K, Kinasz L, Filipecki A et al. Risk factors of asymptomatic restenosis in patients with first anterior ST elevation myocardial infarction treated by primary percutaneous coronary intervention. Kardiol Pol, 2010; 68: 987–993.
- Drewniak W, Snopek G, Zarukiewicz M, Borys M, Dabrowski M. Prognostic value of the N-terminal pro-B-type natriuretic peptide in the elderly with acute myocardial infarction. Kardiol Pol, 2008; 66: 750–755.
- Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA, 2002; 288: 1252–1259.
- Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart, 2005; 91: 606–612.
- Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart, 2006; 92: 843–849.
- Schachner T, Wiedemann D, Fetz H, Laufer G, Kocher A, Bonaros N. Influence of preoperative serum N-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients. Clinics (Sao Paulo), 2010; 65: 1239–1245.
- Cuthbertson BH, Croal BL, Rae D et al. N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study. Br J Anaesth, 2009; 103: 647–653.
- Rodseth RN, Padayachee L, Biccard BM. A meta-analysis of the utility of pre-operative brain natriuretic peptide in predicting early and intermediate-term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia, 2008; 63: 1226–1233.
- Ganem F, Serrano CV, Fernandes JL et al. Preoperative B-type natriuretic peptide, and not the inflammation status, predicts an adverse outcome for patients undergoing heart surgery. Interact Cardiovasc Thorac Surg, doi:10.1510/icvts.2010.255257.
- Nozohoor S, Nilsson J, Algotsson L, Sjögren J. Postoperative increase in B-type natriuretic peptide levels predicts adverse out-

- come after cardiac surgery. J Cardiothorac Vasc Anesth, doi:10.1053/j.2010.07.002.
- Attaran S, Sherwood R, Desai J et al. Brain natriuretic peptide a predictive marker in cardiac surgery. Interact Cardiovasc Thorac Surg, 2009; 9: 662–666.
- Wang Z, Liang D, Fu Q, Jia L, Men J, Wei M. Perioperative brain natriuretic peptide in off-pump coronary artery bypass. Acta Cardiol, 2010; 65: 297–301.
- Hutfless R, Kazanegra R, Madani M et al. Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J Am Coll Cardiol, 2004; 43: 1873–1879.
- 16. Gasparovic H, Burcar I, Kopjar T et al. NT-pro-BNP, but not C-reactive protein, is predictive of atrial fibrillation in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg, 2010; 37: 100–105.
- Gibson PH, Croal BL, Cuthbertson BH et al. Use of preoperative natriuretic peptides and echocardiographic parameters in predicting new-onset atrial fibrillation after coronary artery bypass grafting: a prospective comparative study. Am Heart J, 2009; 158: 244–251.
- Akazawa T, Nishihara H, Iwata H, Warabi K, Ohshima M, Inada E. Preoperative plasma brain natriuretic peptide level is an independent predictor of postoperative atrial fibrillation following off-pump coronary artery bypass surgery. J Anesth, 2008; 22: 347–353.
- Tavakol M, Hassan KZ, Abdula RK et al. Utility of brain natriuretic peptide as a predictor of atrial fibrillation after cardiac operations. Ann Thorac Surg, 2009; 88: 802–807.
- Kolditz M, Halank M, Schiemanck CS, Schmeisser A, Höffken G. High diagnostic accuracy of NT-proBNP for cardiac origin of pleural effusions. Eur Respir J, 2006; 28: 144–150.
- Gegenhuber A, Mueller T, Dieplinger B, Lenz K, Poelz W, Haltmayer M. Plasma B-type natriuretic peptide in patients with pleural effusions: preliminary observations. Chest, 2005; 128: 1003–1009.
- Carmona-Bernal C, Quintana-Gallego E, Villa-Gil M, Sánchez--Armengol A, Martínez-Martínez A, Capote F. Brain natriuretic peptide in patients with congestive heart failure and central sleep apnea. Chest, 2005; 127: 1667–1673.
- Goei D, van Kuijk JP, Flu WJ et al. Usefulness of repeated N-terminal pro-B-type natriuretic Peptide measurements as incremental predictor for long-term cardiovascular outcome after vascular surgery. Am J Cardiol, 2011; 107: 609–614.
- Chello M, Mastroroberto P, Perticone F et al. Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of left ventricular systolic function after coronary artery bypass. Eur J Cardiothorac Surg, 2001; 20: 140–6.
- Fox AA, Muehlschlegel JD, Body SC et al. Comparison of the utility of preoperative versus postoperative B-type natriuretic peptide for predicting hospital length of stay and mortality after primary coronary artery bypass grafting. Anesthesiology, 2010; 112: 842–851.
- 26. Kragelund C, Grønning B, Omland T et al. Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? Am Heart J, 2006; 151: 712.e1–712.e7.
- Ray P, Arthaud M, Lefort Y et al. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med, 2004; 30: 2230–2236.
- Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol, 2006; 47: 345–353.
- Schnabel R, Lubos E, Rupprecht HJ et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol, 2006; 47: 552–558.
- Krzych LJ, Liszka L. No improvement in studies reporting the diagnostic accuracy of B-type natriuretic peptide. Med Sci Monit, 2009; 15: SR5–SR14.

# Trafność diagnostyczna przedoperacyjnego pomiaru stężenia NT-proBNP w przewidywaniu wczesnych powikłań w chirurgii wieńcowej: badanie pilotowe

Łukasz J. Krzych<sup>1, 2</sup>, Dariusz Szurlej<sup>1</sup>, Tadeusz Kołodziej<sup>1</sup>, Leszek Machej<sup>1</sup>, Andrzej Węglarzy<sup>1</sup>, Andrzej Błach<sup>3</sup>, Mirosław Wilczyński<sup>2</sup>, Stanisław Woś<sup>3</sup>, Andrzej Bochenek<sup>2</sup>

### Streszczenie

**Wstęp:** Peptydy natriuretyczne typu B (BNP) są uznanymi markerami ostrej i przewlekłej niewydolności serca. Wartość ich stężenia koreluje z chorobowością i umieralnością, również osób bez jawnych cech niewydolności serca. Wciąż niewystarczająca jest wiedza na temat użyteczności oznaczania stężenia BNP u pacjentów poddawanych operacjom kardiochirurgicznym, w tym chirurgii wieńcowej.

**Cel:** Celem pracy była ocena trafności diagnostycznej przedoperacyjnego pomiaru stężenia NT-proBNP w przewidywaniu wczesnych powikłań pooperacyjnych u chorych poddanych pomostowaniu aortalno-wieńcowemu (CABG).

**Metody:** Badanie miało charakter pilotowy; włączono do niego 100 kolejnych chorych zakwalifikowanych do CABG w trybie planowym; NT-proBNP oznaczano w dniu operacji, przed indukcją znieczulenia. Analizowano częstość występowania wczesnych powikłań pooperacyjnych (30 dni po operacji lub do wypisu ze szpitala).

Wyniki: W badaniu uczestniczyło 24 (24%) kobiet i 76 (76%) mężczyzn. Średni wiek badanych wynosił 65,9 ± 9,1 roku. Wyjściowe ryzyko operacyjne szacowane wg EuroSCORE wynosiło: Me = 4 punkty (IQR 2–7) wg modelu addytywnego oraz Me = 2,90% (IQR 1,75-8,40) wg modelu logistycznego. Mediana NT-proBNP wynosiła 526,0 pg/ml (IQR 156,0-1150,0). Nikt z badanych nie zmarł w okresie pooperacyjnym. Nadmierny drenaż (> 850 ml) dotyczył 13 (13%) osób. Transfuzje krwi i jej preparatów były konieczne u 22 (22%) pacjentów. Przedłużona wentylacja mechaniczna (> 12 h) była konieczna u 15 (15%) chorych, a niewydolność oddechową rozpoznano u 2 (2%) osób. Pooperacyjne AF wystąpiło u 34 (34%) badanych. Okołooperacyjny zawał serca stwierdzono u 2 (2%) chorych, a zespół małego rzutu — u 9 (9%). Wspomaganie hemodynamiczne za pomocą IABP było konieczne u 7 (7%) osób, a za pomocą leków inotropowych — u 61 (61%). Najczęściej stosowano dopaminę: 60 (60%) przypadków, rzadziej adrenalinę (10 chorych) i milrinon (2 osoby). Udar mózgu wystąpił u 1 (1%) osoby, podobnie jak majaczenie. Przedoperacyjne stężenie NT-proBNP znamiennie statystycznie dodatnio korelowało z wyjściowym ryzykiem szacowanym wg algorytmu logistic EuroSCORE (r = 0,558; 95% Cl 0,406–0,680; p < 0,001) i addytywnego EuroSCORE (r = 0,551; 95% CI 0,397–0,674; p < 0,001). Wykazano znamienną ujemną korelację między LVEF a stężeniem peptydu (r = -0.540; 95% CI od -0.666 do -0.384; p < 0.01). Stwierdzono słabą, choć istotną statystycznie, dodatnią zależność między wartościami NT-proBNP a drenażem pooperacyjnym (r = 0,244; 95% CI 0,050–0,421; p = 0,01). Stężenie NT-proBNP istotnie dodatnio korelowało z czasem pobytu na oddziale pooperacyjnym (r = 0,412; 95% CI 0,238– -0,566; p < 0,001) i całkowitym czasem hospitalizacji (r = 0,547; 95% CI 0,393-0,672; p < 0,001). Przedoperacyjna wartość NT-proBNP istotnie statystycznie przewidywała wystąpienie konieczności przedłużonej wentylacji (> 12 h), niewydolności oddechowej, pooperacyjnego AF, konieczności zastosowania IABP, leków inotropowych (dopaminy, adrenaliny i milrinonu) oraz transfuzji koncentratu krwinek płytkowych. Dobrą lub bardzo dobrą trafność diagnostyczną (AUROC > 0,8) w rozpoznawaniu powikłań pooperacyjnych stwierdzono jedynie w przypadku: konieczności przedłużonej wentylacji (AUROC = 0,854), niewydolności oddechowej (AUROC = 0,867), zastosowania IABP (AUROC = 0,889) i milrinonu (AUROC = 0,929).

**Wnioski:** Przedoperacyjna ocena stężenia NT-proBNP u chorych poddawanych CABG może być cenną wskazówką ułatwiającą przewidywanie niektórych powikłań pooperacyjnych.

Słowa kluczowe: NT-proBNP, pomostowanie aortalno-wieńcowe, trafność diagnostyczna, powikłania pooperacyjne

Kardiol Pol 2011; 69, 11: 1121-1127

# Adres do korespondencji:

dr n. med. Łukasz Krzych, I Oddział Kardiochirurgii, SPSK nr 7, Śląski Uniwersytet Medyczny, ul. Ziołowa 45/47, 40–635 Katowice, tel: +48 32 359 86 11, faks: +48 32 252 60 44, e-mail: l.krzych@wp.pl

Praca wpłynęła: 10.03.2011 r. Zaakceptowana do druku: 18.05.2011 r.

<sup>&</sup>lt;sup>1</sup>Zakład Kardioanestezji, Katedra Anestezjologii i Intensywnej Terapii, Śląski Uniwersytet Medyczny, Górnośląskie Centrum Medyczne, Katowice-Ochojec

<sup>&</sup>lt;sup>2</sup>I Katedra i Klinika Kardiochirurgii, Śląski Uniwersytet Medyczny, Górnośląskie Centrum Medyczne, Katowice-Ochojec

<sup>&</sup>lt;sup>3</sup>II Katedra i Klinika Kardiochirurgii, Śląski Uniwersytet Medyczny, Górnośląskie Centrum Medyczne, Katowice-Ochojec